C4X Discovery signs licensing deal worth more than £200m
C4X Discovery, the Manchester-based drug research firm, has signed a licensing deal which could be worth £213m.
The deal has been struck with Indivior UK.
They plan to further develop and commercialise C4XD's Orexin-1 receptor antagonist for the treatment of addiction.
C4X3256 aims to treat addiction by targeting the "craving" process itself and, therefore, can be applied across a broad range of substance use disorders.
The treatment of addiction represents a substantial area of unmet medical need, forecast to be worth an... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
